Entera Bio (NASDAQ:ENTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Entera Bio (NASDAQ:ENTX) announced its quarterly earnings data on Friday. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02, Zacks reports.

Entera Bio Stock Performance

ENTX traded down $0.05 during trading hours on Friday, reaching $1.75. The company’s stock had a trading volume of 55,218 shares, compared to its average volume of 111,862. The company’s 50-day moving average is $2.15 and its 200-day moving average is $2.02. Entera Bio has a 52 week low of $1.41 and a 52 week high of $3.35. The firm has a market cap of $62.62 million, a PE ratio of -6.73 and a beta of 1.62.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a research note on Tuesday, March 18th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.